Anna Maria Ioppolo

Anna Maria Ioppolo

Auto-generated profile, based on publicly available information

Anna Maria Ioppolo

Cardiovascular Department Humanitas Gavazzeni Hospital Bergamo Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
AOAngelo Oliva
Angelo Oliva
AIAnna Maria Ioppolo
Anna Maria Ioppolo
MCMauro Chiarito
Mauro Chiarito
ACAlberto Cremonesi
Alberto Cremonesi
AAAlessia Azzano
Alessia Azzano
DCDavide Cao
Davide Cao
Background: Percutaneous left atrial appendage closure (LAAC) has been suggested as an alternative to long‐term oral anticoagulation for nonvalvular atrial fibrillation, but comparative data remain scarce. We aimed to assess ischemic and bleeding outcomes of LAAC compared with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for the prevention of cardioembolic events in patients with atrial fibrillation. Methods and Results: Embase and MEDLINE were searched for randomized trials comparing LAAC, VKAs, and DOACs. The primary efficacy end point was any stroke or systemic embolism. Treatment effects were calculated from a network meta‐analysis and ranked according to the surface under the cumulative ranking curve. Seven trials and 73 199 patients were included. The risk of the primary end point was not statistically different between LAAC versus VKAs (odds ratio [OR], 0.92 [95% CI, 0.62–1.50]) and LAAC versus DOACs (OR, 1.11 [95% CI, 0.71–1.73]). LAAC and DOACs resulted in similar risk of major or minor (OR, 0.93 [95% CI, 0.61–1.42]) and major bleeding (OR, 0.92 [95% CI, 0.58–1.46]); however, after exclusion of procedural bleeding, bleeding risk was significantly lower in those undergoing LAAC. Both LAAC and DOACs reduced the risk of all‐cause death compared with VKAs (LAAC versus VKAs: OR, 0.70 [95% CI, 0.53–0.91]; DOACs versus VKAs: OR, 0.90 [95% CI, 0.85–0.95], respectively). DOACs ranked as the best treatment for stroke or systemic embolism prevention (66.9%) and LAAC for reducing major bleeding (63.9%) and death (96.4%). Conclusions: As a nonpharmacological alternative to oral anticoagulation for atrial fibrillation, LAAC showed similar efficacy and safety compared with VKAs or DOACs. Prospective confirmation from larger studies is warranted.

1 January 2022 in Journal of Invasive Cardiology
Verified
Journal Article
Closed access
AIAnna Maria Ioppolo
Anna Maria Ioppolo
THThomas Hovasse
Thomas Hovasse
HBHakim Benamer
Hakim Benamer
SCStephane Champagne
Stephane Champagne
BCBernard Chevalier
Bernard Chevalier
FSFrancesca Sanguineti
Francesca Sanguineti
This study aimed to identify angiographic predictors of collateral tracking success, failure, and complications in CTO retrograde approach.